Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.

Bhave P, Ahmed T, Lo SN, Shoushtari A, Zaremba A, Versluis JM, Mangana J, Weichenthal M, Si L, Lesimple T, Robert C, Trojanello C, Wicky A, Heywood R, Tran L, Batty K, Dimitriou F, Stansfeld A, Allayous C, Schwarze JK, Mooradian MJ, Klein O, Mehmi I, Roberts-Thomson R, Maurichi A, Yeoh HL, Khattak A, Zimmer L, Blank CU, Ramelyte E, Kähler KC, Roy S, Ascierto PA, Michielin O, Lorigan PC, Johnson DB, Plummer R, Lebbe C, Neyns B, Sullivan R, Hamid O, Santinami M, McArthur GA, Haydon AM, Long GV, Menzies AM, Carlino MS

Open source

DOI: 10.1136/jitc-2022-004668
Published: 2022 Jul
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2022-004668,
  title = {Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.},
  author = {Bhave P and Ahmed T and Lo SN and Shoushtari A and Zaremba A and Versluis JM and Mangana J and Weichenthal M and Si L and Lesimple T and Robert C and Trojanello C and Wicky A and Heywood R and Tran L and Batty K and Dimitriou F and Stansfeld A and Allayous C and Schwarze JK and Mooradian MJ and Klein O and Mehmi I and Roberts-Thomson R and Maurichi A and Yeoh HL and Khattak A and Zimmer L and Blank CU and Ramelyte E and Kähler KC and Roy S and Ascierto PA and Michielin O and Lorigan PC and Johnson DB and Plummer R and Lebbe C and Neyns B and Sullivan R and Hamid O and Santinami M and McArthur GA and Haydon AM and Long GV and Menzies AM and Carlino MS},
  year = {2022},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2022-004668},
  url = {https://doi.org/10.1136/jitc-2022-004668}
}

RIS

TY  - JOUR
TI  - Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
AU  - Bhave P
AU  - Ahmed T
AU  - Lo SN
AU  - Shoushtari A
AU  - Zaremba A
AU  - Versluis JM
AU  - Mangana J
AU  - Weichenthal M
AU  - Si L
AU  - Lesimple T
AU  - Robert C
AU  - Trojanello C
AU  - Wicky A
AU  - Heywood R
AU  - Tran L
AU  - Batty K
AU  - Dimitriou F
AU  - Stansfeld A
AU  - Allayous C
AU  - Schwarze JK
AU  - Mooradian MJ
AU  - Klein O
AU  - Mehmi I
AU  - Roberts-Thomson R
AU  - Maurichi A
AU  - Yeoh HL
AU  - Khattak A
AU  - Zimmer L
AU  - Blank CU
AU  - Ramelyte E
AU  - Kähler KC
AU  - Roy S
AU  - Ascierto PA
AU  - Michielin O
AU  - Lorigan PC
AU  - Johnson DB
AU  - Plummer R
AU  - Lebbe C
AU  - Neyns B
AU  - Sullivan R
AU  - Hamid O
AU  - Santinami M
AU  - McArthur GA
AU  - Haydon AM
AU  - Long GV
AU  - Menzies AM
AU  - Carlino MS
PY  - 2022
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2022-004668
UR  - https://doi.org/10.1136/jitc-2022-004668
ER  -

APA

P, B., T, A., SN, L., A, S., A, Z., JM, V., J, M., M, W., L, S., T, L., C, R., C, T., A, W., R, H., L, T., K, B., F, D., A, S., C, A., JK, S., MJ, M., O, K., I, M., R, R., A, M., HL, Y., A, K., L, Z., CU, B., E, R., KC, K., S, R., PA, A., O, M., PC, L., DB, J., R, P., C, L., B, N., R, S., O, H., M, S., GA, M., AM, H., GV, L., AM, M., & MS, C. (2022). Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2022-004668

Source records

pubmed · retrieved 2026-09-26T11:28:54.767Z